MedTrace Logo

Prognostic Factors and the Impact of Various Management of Acute Myeloid Leukemia in Real Life Condition

NCT03284593 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 199

Last updated 2020-07-30

No results posted yet for this study

Summary

The treatment of older patients with acute myeloid leukemia that is secondary to previous myelodysplastic syndrome, myeloproliferative neoplasm, or prior cytotoxic exposure remains unsatisfactory. We compared patients treated with intensive chemotherapy or azacitidine within two centres.

Conditions

Interventions

DRUG

intensive chemotherapy

DRUG

Azacitidine

Sponsors & Collaborators

  • University Hospital, Toulouse

    lead OTHER

Principal Investigators

  • Christian RECHER, MD · University Hospital, Toulouse

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2030-12-31
Completion
2030-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03284593 on ClinicalTrials.gov